Phase II study of bevacizumab and vorinostat for recurrent glioblastoma.

Authors

Ashley Ghiaseddin

Ashley Ghiaseddin

Duke University Medical Center, Durham, NC

Ashley Ghiaseddin , David A. Reardon , Woody Massey , Alexandra Mannerino , Eric S. Lipp , James E. Herndon II, Frances McSherry , Annick Desjardins , Dina M Randazzo , Gordana Vlahovic , Henry S. Friedman , Katherine B Peters

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2015 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Central Nervous System Tumors

Track

Central Nervous System Tumors

Sub Track

Central Nervous System Tumors

Clinical Trial Registration Number

NCT01738646

Citation

J Clin Oncol 33, 2015 (suppl; abstr 2034)

DOI

10.1200/jco.2015.33.15_suppl.2034

Abstract #

2034

Poster Bd #

23

Abstract Disclosures

Similar Posters

First Author: Manmeet Singh Ahluwalia

First Author: Jaleh Fallah

Poster

2012 ASCO Annual Meeting

Vorinostat, temozolomide, and bevacizumab for patients with recurrent glioblastoma: A phase I/II trial.

Vorinostat, temozolomide, and bevacizumab for patients with recurrent glioblastoma: A phase I/II trial.

First Author: Katherine B. Peters